The HDAC inhibitors scriptaid and LBH589 combined with the oncolytic virus Delta24-RGD exert enhanced anti-tumor efficacy in patient-derived glioblastoma cells

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Pont, Lotte M E Berghauser ^a   Kleijn, Anne ^a   Kloezeman, Jenneke J ^a   Van Bossche, Wouter Den ^a   Kaufmann, Johanna K ^b   De Vrij, Jeroen ^c   Leenstra, Sieger ^a,d   Dirven, Clemens M F ^a   Lamfers, Martine L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; CASPASE 3; CASPASE 7; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DELTA24 RGD; ENTINOSTAT; GREEN FLUORESCENT PROTEIN; LUCIFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; PANOBINOSTAT; RETINOBLASTOMA PROTEIN; S6 KINASE; UNCLASSIFIED DRUG; VALPROIC ACID; VITRONECTIN RECEPTOR; VORINOSTAT; DNA LIGASE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXYLAMINE; INDOLE DERIVATIVE; MGMT PROTEIN, HUMAN; ONCOLYTIC VIRUS; PROTEIN P53; QUINOLINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ADENOVIRIDAE; ADENOVIRUS INFECTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; AUTOPHAGY; CANCER STEM CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; LIGHT CHAIN; MGMT GENE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TOXICITY TESTING; VIRUS REPLICATION; VIRUS TITRATION; ANIMAL; BRAIN NEOPLASMS; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETICS; GLIOBLASTOMA; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PROMOTER REGION;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; ASTROCYTES; AUTOPHAGY; BRAIN NEOPLASMS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYDROXYLAMINES; INDOLES; INTEGRIN ALPHAVBETA3; MICE; MUTATION; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; QUINOLINES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930624813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127058     Document Type: Article

References (40)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10 (5):459-66. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895.
2. Lang FF, Conrad C, Gomez-Manzano C, Tufaro F, Yung W, Sawaya R, et al. First-in-human phase I clinical trial of oncolytic delta-24-rgd (dnx-2401) with biological endpoints: implications for viro- immunotherapy. Neuro Oncol. 2014; 16 Suppl 3:iii39. doi: 10.1093/neuonc/nou208.61 PMID: 25165314; PubMed Central PMCID: PMC4144610.
3. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002; 62(20):5736-42. PMID: 12384532.
4. Singh N. Apoptosis in health and disease and modulation of apoptosis for therapy: An overview. Indian journal of clinical biochemistry: IJCB. 2007; 22(2):6-16. doi: 10.1007/BF02913307 PMID: 23105676; PubMed Central PMCID: PMC3453819.
5. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol. 2004; 78(22):12243-51. doi: 10.1128/JVI.78.22.12243-12251. 2004 PMID: 15507611; PubMed Central PMCID: PMC525077.
6. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. Journal of the National Cancer Institute. 2007; 99(18):1410-4. doi: 10.1093/jnci/djm102 PMID: 17848677.
7. Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 2001; 61(7):2953-60. PMID: 11306473.
8. de Jonge J, Berghauser Pont LM, Idema S, Kloezeman JJ, Noske D, Dirven CM, et al. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma. J Gene Med. 2013; 15(3-4):134-41. Epub 2013/04/23. doi: 10.1002/jgm.2703 PMID: 23606319.
9. Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Advances in cancer research. 2012; 116:199-237. doi: 10.1016/B978-0-12-394387-3.00006-9 PMID: 23088872.
10. Monneret C. Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs. 2007; 18(4):363-70. doi: 10.1097/CAD.0b013e328012a5db PMID: 17351388.
11. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012; 109 (17):6561-5. Epub 2012/04/12. 1204429109 [pii] doi: 10.1073/pnas.1204429109 PMID: 22493260; PubMed Central PMCID: PMC3340088.
12. Kim DR, Park MY, Lim HJ, Park JS, Cho YJ, Lee SW, et al. Combination therapy of conditionally replicating adenovirus and histone deacetylase inhibitors. Int J Mol Med. 2012; 29(2):218-24. doi: 10.3892/ijmm.2011.831 PMID: 22075951.
13. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. Epub 2006/05/16. S1535-6108(06)00117-6 [pii] doi: 10.1016/j.ccr.2006.03.030 PMID: 16697959.
14. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res. 2001; 7(1):120-6. PMID: 11205899.
15. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature biotechnology. 1997; 15(6):542-6. doi: 10.1038/nbt0697-542 PMID: 9181576.
16. Balvers RK, Belcaid Z, van den Hengel SK, Kloezeman J, de Vrij J, Wakimoto H, et al. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma. Viruses. 2014; 6(8):3080-96. doi: 10.3390/v6083080 PMID: 25118638; PubMed Central PMCID: PMC4147687.
17. Balvers RK, Kleijn A, Kloezeman JJ, French PJ, Kremer A, van den Bent MJ, et al. Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. Neuro Oncol. 2013; 15(12):1684-95. doi: 10.1093/neuonc/not116 PMID: 24046260; PubMed Central PMCID: PMC3829587.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation. 1984; 22:27-55. PMID: 6382953.
19. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251; PubMed Central PMCID: PMC2818769.
20. Berghauser Pont LM, Naipal K, Kloezeman JJ, Venkatesan S, van den Bent M, van Gent DC, et al. DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells. Cancer Lett. 2014. doi: 10.1016/j.canlet.2014.09.049 PMID: 25305451.
21. Berghauser Pont LM, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, et al. The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes Cancer. 2014; 5(11-12):445-59. PMID: 25568669; PubMed Central PMCID: PMC4279441.
22. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. Epub 2010/02/05. S1535-6108(09)00432-2 [pii] doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251; PubMed Central PMCID: PMC2818769.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. doi: 10.1158/0008-5472.CAN-09-1947 PMID: 20068163.
24. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Molecular therapy: the journal of the American Society of Gene Therapy. 2008; 16(9):1546-55. doi: 10.1038/mt.2008.155 PMID: 18648350.
25. Sasaki Y, Negishi H, Idogawa M, Suzuki H, Mita H, Toyota M, et al. Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Mol Cancer Ther. 2008; 7(4):779-87. doi: 10.1158/1535-7163.MCT-07-0395 PMID: 18413792.
26. Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, et al. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol Cancer Ther. 2007; 6(2):496-505. doi: 10.1158/1535-7163.MCT-06-0431 PMID: 17308048.
27. MacTavish H, Diallo JS, Huang B, Stanford M, Le Boeuf F, De Silva N, et al. Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One. 2010; 5(12):e14462. doi: 10.1371/journal.pone.0014462 PMID: 21283510; PubMed Central PMCID: PMC3012680.
28. Hoti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther. 2006; 14(6):768-78. doi: 10.1016/j.ymthe.2006.07.009 PMID: 16990052.
29. Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, et al. Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer. 2011; 11:375. doi: 10.1186/1471-2407-11-375 PMID: 21867506; PubMed Central PMCID: PMC3170298.
30. Ma J, Zhao J, Lu J, Jiang Y, Yang H, Li P, et al. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. Int J Mol Med. 2012; 30(6):1403-9. doi: 10.3892/ijmm.2012.1133 PMID: 22992863.
31. Sachs MD, Ramamurthy M, Poel H, Wickham TJ, Lamfers M, Gerritsen W, et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther. 2004; 11(7):477-86. Epub 2004/05/01. doi: 10.1038/sj.cgt.77007267700726 [pii]. PMID: 15118762.
32. Wu W, Dong YW, Shi PC, Yu M, Fu D, Zhang CY, et al. Regulation of integrin alphaV subunit expression by sulfatide in hepatocellular carcinoma cells. J Lipid Res. 2013; 54(4):936-52. doi: 10.1194/jlr.M031450 PMID: 23345412; PubMed Central PMCID: PMC3606000.
33. Simboeck E, Sawicka A, Zupkovitz G, Senese S, Winter S, Dequiedt F, et al. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem. 2010; 285(52):41062-73. doi: 10.1074/jbc.M110.184481 PMID: 20952396; PubMed Central PMCID: PMC3003405.
34. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther. 2008; 16(3):487-93. doi: 10.1038/sj.mt.6300400 PMID: 18253154.
35. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009; 14(4):364-75. doi: 10.1007/s10495-008-0303-9 PMID: 19145485.
36. Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW. The role of p21(waf1/cip1) and p27 (Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B-cell lymphoma. Oncogene. 2014; 33(47):5415-23. doi: 10.1038/onc.2013.482 PMID: 24292681.
37. Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, et al. The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity. PLoS One. 2014; 9(5):e97495. doi: 10.1371/journal.pone.0097495 PMID: 24866126; PubMed Central PMCID: PMC4035348.
38. Jiang H, Clise-Dwyer K, Ruisaard KE, Fan X, Tian W, Gumin J, et al. Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One. 2014; 9(5):e97407. doi: 10.1371/journal.pone.0097407 PMID: 24827739; PubMed Central PMCID: PMC4020829.
39. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A, Nemunaitis J. Oncolytic viruses for induction of anti-tumor immunity. Current pharmaceutical biotechnology. 2012; 13(9):1750-60. PMID: 21740355.
40. Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol. 2012; 90(1):55-65. doi: 10.1038/icb.2011.96 PMID: 22105512; PubMed Central PMCID: PMC3990411.